2D-BioPAD took center stage at the 14th Panhellenic Conference on Alzheimer’s Disease & 6th Mediterranean Conference on Neurodegenerative Diseases, from February 13th-16th, 2025, at the Grand Hotel Palace in Thessaloniki. The conference, organised by our partner Alzheimer Hellas and the Panhellenic Institute of Neurodegenerative Diseases, offered a unique chance for professionals to learn about the latest research on dementia and neurodegenerative diseases.
One of the highlights of the event was a session on Erasmus + and HORIZON projects held on February 13th from 12:30-13:30 (CET), focusing on the 2D-BioPAD project.
Key Presentations:
- “Clinical Validation of a Novel Point-of-Care Diagnostic Aid for Early Detection and Monitoring of Alzheimer’s Disease” by Anthoula Tsolaki.
- “Socio-economic and Clinical Needs and Challenges in Early Detection and Monitoring Alzheimer’s Disease in Primary Healthcare in Greece” by Foteini Aikaterini Pikouli and Maria Aivazoglou.
A key takeaway from the event was the pressing need for improved education, as 91% of healthcare professionals (HCPs) were unfamiliar with Alzheimer’s biomarker protocols, underscoring the importance of awareness initiatives. Additionally, cost and accessibility challenges remain significant barriers in Greece, with calls for better insurance coverage and reimbursement policies to support wider adoption of diagnostic tools.
Despite these challenges, 2D-BioPAD is emerging as a game-changer, offering a fast, cost-effective, and non-invasive solution for primary care settings. By addressing critical gaps in detection and monitoring, this technology brings renewed hope to both patients and healthcare providers.
